Hsbc Holdings PLC boosted its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 132.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 84,817 shares of the biotechnology company's stock after acquiring an additional 48,310 shares during the period. Hsbc Holdings PLC owned 0.17% of REGENXBIO worth $629,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after purchasing an additional 1,659,206 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of REGENXBIO by 1.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company's stock valued at $9,054,000 after buying an additional 21,234 shares in the last quarter. Geode Capital Management LLC raised its position in shares of REGENXBIO by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock valued at $8,460,000 after buying an additional 5,574 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock worth $6,621,000 after acquiring an additional 296,700 shares during the period. Finally, Norges Bank acquired a new stake in shares of REGENXBIO during the 4th quarter worth approximately $3,474,000. 88.08% of the stock is owned by institutional investors and hedge funds.
REGENXBIO Trading Up 5.2 %
NASDAQ:RGNX traded up $0.37 during mid-day trading on Friday, hitting $7.52. 872,904 shares of the company's stock were exchanged, compared to its average volume of 847,465. REGENXBIO Inc. has a fifty-two week low of $5.04 and a fifty-two week high of $16.85. The firm has a market capitalization of $376.88 million, a P/E ratio of -1.50 and a beta of 1.11. The company has a 50 day simple moving average of $7.32 and a 200-day simple moving average of $8.02.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.26. The company had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. As a group, analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current year.
Analysts Set New Price Targets
RGNX has been the subject of several recent analyst reports. HC Wainwright cut their target price on REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, March 17th. Raymond James started coverage on REGENXBIO in a research note on Friday, February 7th. They issued an "outperform" rating and a $27.00 price objective on the stock. Chardan Capital reiterated a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 20th. StockNews.com raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $31.63.
Get Our Latest Analysis on REGENXBIO
About REGENXBIO
(
Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
